From Health Canada:
AstraZeneca Canada Inc. in consultation with Health Canada would like to update you on the outcomes of the US FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting held on July 13, 2005 to review the safety of the long-acting beta agonists salmeterol and formoterol. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment